Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis C

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    September 2019
  1. ZOU B, Yeo YH, Le MH, Henry L, et al
    Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.
    J Infect Dis. 2019 Sep 27. pii: 5575100. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2019
  2. EMMANUEL B, El-Kamary SS, Magder LS, Stafford KA, et al
    Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-DeltaG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.
    J Infect Dis. 2019 Aug 26. pii: 5554606. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2019
  3. MARTIN NK, Jansen K, An der Heiden M, Boesecke C, et al
    Can HCV be eliminated among HIV-positive men who have sex with men in Berlin? A modeling analysis.
    J Infect Dis. 2019 Jul 12. pii: 5532024. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2019
  4. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis C.
    J Infect Dis. 2019 Jun 4. pii: 5511345. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. HAN JW, Sung PS, Kim KH, Hong SH, et al
    Dynamic Changes in Ex Vivo T-Cell Function after Viral Clearance in Chronic HCV Infection.
    J Infect Dis. 2019 Jun 1. pii: 5510067. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2019
  6. YAN Y, Wang X, Lou P, Hu Z, et al
    A nanoparticle-based HCV vaccine with enhanced potency.
    J Infect Dis. 2019 May 10. pii: 5487910. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. LAIDLAW SM, Dustin LB
    An HCV vaccine on the fly.
    J Infect Dis. 2019 May 10. pii: 5487908. doi: 10.1093.
    PubMed     Text format    


    April 2019
  8. DOUGLAS MW, Tay ES, Eden JS, George J, et al
    Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir.
    J Infect Dis. 2019 Apr 8. pii: 5431216. doi: 10.1093.
    PubMed     Text format    


  9. HUANG CF, Hung CH, Cheng PN, Bair MJ, et al
    An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated subst
    J Infect Dis. 2019 Apr 8. pii: 5430846. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2019
  10. ABARA WE, Trujillo L, Broz D, Finlayson T, et al
    Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015.
    J Infect Dis. 2019 Mar 27. pii: 5420467. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  11. SALAZAR-VIZCAYA L, Kouyos RD, Metzner KJ, Caraballo Cortes K, et al
    Changing trends in international versus domestic HCV transmission in HIV-positive MSM: A perspective for the DAA scale-up era.
    J Infect Dis. 2019 Feb 13. pii: 5318573. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. LEUNG J, Peacock A, Colledge S, Grebely J, et al
    A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?
    J Infect Dis. 2019 Feb 6. pii: 5307802. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2019
  13. RAGHWANI J, Wu CH, Ho CKY, De Jong M, et al
    High resolution evolutionary analysis of within-host hepatitis C virus infection.
    J Infect Dis. 2019 Jan 2. pii: 5269822. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  14. PIROZYAN MR, Nguyen N, Cameron B, Luciani F, et al
    Chemokine-regulated recruitment of antigen-specific T cell sub-populations to the liver in acute and chronic hepatitis C infection.
    J Infect Dis. 2018 Nov 29. pii: 5213654. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. PRICE JC, McKinney JE, Crouch PC, Dillon SM, et al
    Sexually Acquired Hepatitis C Infection in HIV-uninfected Men Who Have Sex with Men Using Pre-exposure Prophylaxis Against HIV.
    J Infect Dis. 2018 Nov 20. pii: 5193510. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. YEH ML, Huang CI, Huang CF, Hsieh MH, et al
    Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients.
    J Infect Dis. 2018 Nov 19. pii: 5191105. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  17. LAROUCHE A, Milton McSween KA, Calderon V, Fauteux-Daniel S, et al
    Quasispecies Diversity Is a Major Risk Factor for Vertical Hepatitis C Virus Transmission.
    J Infect Dis. 2018 Oct 25. pii: 5144832. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  18. THOENS C, Heinold A, Lindemann M, Horn PA, et al
    A single nucleotide polymorphism upstream of the HLA-C locus is associated with an anti-HCV seronegative state in a high-risk exposed cohort.
    J Infect Dis. 2018 Aug 9. pii: 5068404. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. VELAZQUEZ-MOCTEZUMA R, Galli A, Law M, Bukh J, et al
    Hepatitis C virus escape studies for human monoclonal antibody AR4A reveal isolate-specific resistance and a high barrier to resistance.
    J Infect Dis. 2018 Aug 9. pii: 5068268. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  20. LOPEZ-CORTES LF, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo OJ, et al
    Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    J Infect Dis. 2018 Jul 6. pii: 5050122. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  21. BORGIA SM, Hedskog C, Parhy B, Hyland RH, et al
    Identification of a Novel Hepatitis C Virus Genotype from Punjab, India - Expanding Classification of Hepatitis C Virus into 8 Genotypes.
    J Infect Dis. 2018 Jun 30. pii: 5047409. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. HELFRITZ FA, Bojkova D, Wanders V, Kuklinski N, et al
    Methylene Blue Treatment of Grafts during Cold Ischemia time Reduces the Risk of HCV Transmission.
    J Infect Dis. 2018 Jun 23. pii: 5043304. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. LIDOFSKY A, Holmes JA, Feeney ER, Kruger AJ, et al
    Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection.
    J Infect Dis. 2018 Jun 4. pii: 5032604. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  24. RAGONNET-CRONIN M, Jackson C, Bradley-Stewart A, Aitken C, et al
    Recent and Rapid Transmission of HIV among People who Inject Drugs in Scotland Revealed through Phylogenetic Analysis.
    J Infect Dis. 2018 Mar 13. pii: 4931169. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. COOPER CL
    Now is the Time to Quickly Eliminate Barriers along the Hepatitis C Cascade of Care.
    J Infect Dis. 2018 Mar 9. pii: 4925219. doi: 10.1093.
    PubMed     Text format    


  26. LAMOURY FMJ, Bajis S, Hajarizadeh B, Marshall AD, et al
    Evaluation of the Xpert(R) HCV Viral Load Fingerstick point-of-care assay.
    J Infect Dis. 2018 Mar 9. pii: 4925218. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. STROUVELLE VP, Braun DL, Vongrad V, Scherrer AU, et al
    No Effect of Pegylated Interferon-alpha on Total Hiv-1 DNA Load in HIV-1/HCV Coinfected Patients.
    J Infect Dis. 2018 Mar 8. pii: 4924783. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018

  28. Erratum: Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2018 Jan 27. pii: 4827080. doi: 10.1093.
    PubMed     Text format    


  29. ROLT A, Le D, Hu Z, Wang AQ, et al
    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. SANAKA S, Kasarala GR, Tillmann HL
    A Downside to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression.
    J Infect Dis. 2018 Jan 21. pii: 4770294. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. REID M, Ma Y, Scherzer R, Price JC, et al
    Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
    J Infect Dis. 2018 Jan 3. pii: 4786614. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  32. PERUMALSWAMI PV, Talal AH
    Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders.
    J Infect Dis. 2017 Dec 26. pii: 4774700. doi: 10.1093.
    PubMed     Text format    


  33. STEPANOVA M, Thompson A, Doyle J, Younossi I, et al
    Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
    J Infect Dis. 2017 Dec 26. pii: 4774699. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  34. ROSENBERG BR, Freije CA, Imanaka N, Chen ST, et al
    Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  37. TALAL AH, Dumas EO, Bauer B, Rejman RM, et al
    Hepatic Pharmacokinetics and Pharmacodynamics with Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
    J Infect Dis. 2017 Sep 27. pii: 4210613. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  38. HEIMER R, Binka M, Koester S, Grund JC, et al
    Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


    April 2017
  40. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  41. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  42. HALLAGER S, Brehm Christensen P, Ladelund S, Rye Clausen M, et al
    Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population - a Danish cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  43. HENGST J, Falk CS, Schlaphoff V, Deterding K, et al
    DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  44. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  45. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: